Danish trial demonstrates benefits of dual-chamber pacing in treating sick sinus syndrome

Aug 31, 2010

DANPACE, a Danish multicentre randomised trial comparing single lead atrial and dual chamber pacing in patients with sick sinus syndrome, concludes that dual chamber pacing, which was associated with lower rates of atrial fibrillation and re-operation, "should be the preferred pacing mode".

Behind the conclusion lies a 20-site study of 1415 subjects with sick sinus syndrome (a variety of arrhythmias caused by a malfunction of the sinus node, the heart's principal pacemaker) referred for their first pacemaker implantation. Pacemakers are routinely used to treat patients suffering from sick sinus syndrome.

The patients were randomised equally to single-lead atrial or dual-chamber pacemakers* and their progress followed for a mean of 6.4 years, producing over 7000 operational years of evidence. Results showed that all-cause were similar in both groups, 29.6% in the single-lead atrial pacemaker group and 27.3% in the dual chamber group. However, the prevalence of paroxysmal atrial fibrillation was lower in the dual chamber group than in the single-lead group (HR 0.79, p=0.024), with significantly fewer dual chamber patients requiring pacemaker re-operation during follow-up (HR 0.50, p<0.001).

Summarising the outcome, principal investigator Dr Jens Cosedis Nielsen from the Department of Cardiology, Skejby Hospital in Aarhus, Denmark, said: “The results showed that, when compared with dual-chamber pacing, single-lead atrial pacing was associated with a 27% increase in the risk of developing atrial fibrillation and a doubling of the risk of having to undergo a pacemaker re-operation.

“In prior trials, ventricular stimulation has been found to increase the incidences of atrial fibrillation and heart failure. However, in this patient group we demonstrated for the first time that dual-chamber pacing actually decreases atrial fibrillation and has no influence on the incidence of when compared with single-lead atrial pacing without ventricular stimulation.”

Explore further: Hormonal therapy for transsexualism safe and effective

add to favorites email to friend print save as pdf

Related Stories

Osteoporosis drug may be associated with irregular heartbeat

Apr 28, 2008

Alendronate, a medication used to prevent fractures in women with osteoporosis, may be associated with an increased risk of atrial fibrillation, a type of abnormal heart rhythm, according to a report in the April 28 issue ...

Recommended for you

Hormonal therapy for transsexualism safe and effective

10 hours ago

Hormonal therapy for transsexual patients is safe and effective, a multicenter European study indicates. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.

Royalty Pharma lets Elan takeover bid expire

14 hours ago

Royalty Pharma has let its latest takeover bid for Irish drugmaker Elan lapse as it decided against pressing ahead with a court challenge of a requirement that it withdraw the offer.

FDA approves new silicone breast implants

Jun 17, 2013

(HealthDay)—MemoryShape breast implants have been approved by the U.S. Food and Drug Administration for breast augmentation in women 22 and older, and for breast reconstruction, the FDA said Friday.

User comments : 0

More news stories

3D printing tiny batteries

(Phys.org) —3D printing can now be used to print lithium-ion microbatteries the size of a grain of sand. The printed microbatteries could supply electricity to tiny devices in fields from medicine to communications, ...